Miller Barondess Files Lawsuit Against Nissan North America Over Alleged Scheme to Undermine Successful Automotive Dealer
Trophy Universal City Group, LLC and Trophy West Covina Motor Group, LLC (“Trophy Group”) have filed a lawsuit against Nissan North America, Inc., accusing the automaker of orchestrating a deliberate and nefarious scheme to suffocate vehicle inventory and squeeze out the Trophy Group. The case centers on two Los Angeles County Nissan dealerships—Universal City Nissan and West Covina Nissan—led by global automotive entrepreneur and Trophy Group founder and CEO, Nasser Watar, only to face what Trophy Group alleges is retaliatory sabotage by Nissan. Trophy Group is represented by Amnon Siegel and Bryan Redfern of Miller Barondess, LLP.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327109484/en/
A Legacy of Success and Partnership
Since Trophy Group’s founding more than ten years ago, Nasser Watar, a veteran of the automotive industry, expanded Trophy Group to operate numerous successful dealerships in Southern California, including leading brands such as Mercedes-Benz and Kia. Its dealerships rank among the top-selling in the nation for their respective brands.
In addition to his U.S. operations, Watar has played a significant role in Nissan’s international distribution, particularly in the Middle East. From 2008 to 2019, he served as Vice Chairman, President and CEO of Nissan Gulf Company, a joint venture between Nissan Motor Co., Ltd. (“Nissan Japan”) and Al-Dahana Group. During Al-Dahana’s joint venture with Nissan Japan, Watar was CEO of Al-Dahana, as well as Nissan Gulf. Under Watar’s leadership, Nissan Gulf significantly expanded Nissan’s market presence, becoming the second-largest market leader in the Middle East and the most profitable Nissan subsidiary worldwide.
Nissan’s Initial Plea for Help
In 2017, recognizing Watar’s expertise, Nissan approached him to take over two struggling Los Angeles County dealerships—Universal City Nissan and West Covina Nissan. These once-successful dealerships had fallen into financial distress under their previous owner, Sage Automotive Group. Nissan sought Watar’s leadership to restore them to profitability, and Trophy Group acquired the dealerships. Initially, the transition was positive. With Nissan’s support, Watar and his team worked diligently to rebuild the dealerships’ reputation and performance.
Retaliation Following the Ghosn Scandal
In 2018, the arrest of former Nissan Japan CEO Carlos Ghosn sparked global controversy. As details emerged, Nissan Japan sought to sever ties with individuals and entities linked to the scandal—including Watar’s former business partner at Al-Dahana. Despite no allegations against Watar himself, Nissan unilaterally terminated its Gulf distribution partnership, prompting Al-Dahana to file suit. In 2021, Al-Dahana secured a $354 million judgment against Nissan Japan in Dubai.
In response, Nissan allegedly undertook a secret retaliatory campaign against Watar and Trophy Group’s U.S. dealerships, aiming to drive them out of business. Per the complaint, Nissan systematically under-allocated vehicles to Universal City Nissan and West Covina Nissan, depriving them of essential inventory while favoring nearby competitors.
The Impact of Nissan’s Unlawful Actions
New vehicle allocation is the lifeblood of any dealership, and Nissan’s alleged actions created a devastating cycle: reduced inventory led to lower sales, which in turn resulted in further reduced allocations. Despite Watar’s repeated pleas for fair treatment, Nissan allegedly refused to provide the necessary inventory, deliberately crippling the Trophy Group’s Nissan dealerships and eventually forcing them to close their doors.
Nissan’s alleged actions have resulted in millions in damages to Trophy Group and have also deprived consumers of competitive options in the Los Angeles market. Trophy Group is pursuing all available legal remedies against Nissan for its alleged targeted campaign of economic destruction.
“Nissan’s conduct represents an abuse of power and a blatant disregard for proper and fair business practices,” said Amnon Siegel. “We will not allow Nissan to unlawfully eliminate a trusted and dedicated dealer through manipulation and bad faith and look forward to the opportunity to present our case to a jury.”
The case is Trophy Universal City Group, LLC, et al. v. Nissan North America, Inc., et al., Los Angeles County Superior Court, Case No. [pending]
About Miller Barondess, LLP:
Miller Barondess, LLP is a Los Angeles-based law firm that specializes in litigation, including trial, arbitration, and appellate proceedings in California and nationwide. The firm represents both plaintiffs and defendants across a wide range of sectors, including automotive, consumer products, private equity, securities, financial services, intellectual property, patents, licensing and branding, technology and cybersecurity, real estate, healthcare, entertainment and music, sports, insurance, retail, environmental, and government. With a reputation for winning bet-the-company litigation, the firm is frequently engaged to resolve pivotal issues before trial, and other law firms bring in Miller Barondess when their clients need a trial or appellate team.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327109484/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom